National Comprehensive Cancer Network® (NCCN) Guidelines® Version 03/2022
(NCCN) Guidelines® Version 3.2022 for prostate cancer now contains a
We make the complex, simple.
By developing advanced solutions that change lives. Always one step ahead, for you.
Advancing cancer diagnosis and therapy is among the most critical and worthy goals for humanity.
At ISOTOPIA, this goal is our mission.
Isotopia Molecular Imaging is a global pharmaceutical company that develops, produces, and distributes cutting-edge diagnostic and therapeutic radioactive isotopes and advanced PET and SPECT radiotracers.
We are a multidisciplinary team of experts unified in the mission to expand healthcare providers’ power to diagnose and treat cancer, with greater precision and safety.
(NCCN) Guidelines® Version 3.2022 for prostate cancer now contains a
Petach Tikva, Israel, and Beijing China 19 Oct 2021 Petach
October 31st, 2021 – Petach Tikva, Israel and Melbourne, Australia